The Denmark-based biotech company, Nordic Bioscience, has completed enrollment of patients for a major phase II study conducted on behalf of German pharma giant Merck ahead of schedule – which makes the company hope for more.
by Stefan Singh Kailay
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.